Insmed Incorporated (NASDAQ:INSM) Stake Lessened by Emerald Mutual Fund Advisers Trust

Emerald Mutual Fund Advisers Trust trimmed its position in Insmed Incorporated (NASDAQ:INSM) by 17.8% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 400,624 shares of the biopharmaceutical company’s stock after selling 87,040 shares during the period. Insmed comprises 1.7% of Emerald Mutual Fund Advisers Trust’s portfolio, making the stock its 10th biggest holding. Emerald Mutual Fund Advisers Trust owned about 0.22% of Insmed worth $27,659,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Steward Partners Investment Advisory LLC boosted its position in shares of Insmed by 65.2% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 163 shares during the period. V Square Quantitative Management LLC boosted its holdings in Insmed by 60.3% in the 4th quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company’s stock worth $45,000 after buying an additional 248 shares during the period. Spire Wealth Management purchased a new stake in Insmed in the 4th quarter worth $47,000. Smartleaf Asset Management LLC raised its holdings in Insmed by 98.1% during the fourth quarter. Smartleaf Asset Management LLC now owns 830 shares of the biopharmaceutical company’s stock valued at $57,000 after acquiring an additional 411 shares during the period. Finally, Venturi Wealth Management LLC purchased a new position in shares of Insmed in the fourth quarter valued at about $86,000.

Insider Activity at Insmed

In other Insmed news, insider Martina M.D. Flammer sold 33,055 shares of the company’s stock in a transaction on Thursday, February 6th. The stock was sold at an average price of $80.90, for a total value of $2,674,149.50. Following the completion of the sale, the insider now directly owns 138,053 shares in the company, valued at approximately $11,168,487.70. This represents a 19.32 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO William Lewis sold 18,750 shares of the stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $77.94, for a total value of $1,461,375.00. Following the transaction, the chief executive officer now directly owns 379,534 shares in the company, valued at $29,580,879.96. The trade was a 4.71 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 471,797 shares of company stock worth $37,621,239. Company insiders own 3.00% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. Truist Financial boosted their price target on Insmed from $105.00 to $108.00 and gave the stock a “buy” rating in a report on Friday, February 21st. HC Wainwright reaffirmed a “buy” rating and issued a $90.00 price objective on shares of Insmed in a research note on Tuesday, April 22nd. Morgan Stanley boosted their price target on shares of Insmed from $85.00 to $90.00 and gave the stock an “overweight” rating in a research report on Thursday, February 6th. Guggenheim reiterated a “buy” rating and set a $101.00 price objective on shares of Insmed in a research report on Tuesday, February 25th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Insmed from $83.00 to $92.00 and gave the stock an “overweight” rating in a report on Friday, February 7th. One equities research analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $94.00.

Insmed Stock Performance

Shares of Insmed stock opened at $69.69 on Monday. Insmed Incorporated has a 52 week low of $21.92 and a 52 week high of $84.91. The company has a market capitalization of $12.67 billion, a PE ratio of -12.47 and a beta of 1.07. The stock’s fifty day moving average is $74.38 and its two-hundred day moving average is $73.57. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03.

Insmed (NASDAQ:INSM) last announced its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.15). The company had revenue of $104.44 million for the quarter, compared to the consensus estimate of $102.31 million. Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. As a group, analysts expect that Insmed Incorporated will post -4.56 earnings per share for the current year.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.